S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$19.31
+0.6%
$21.53
$9.26
$26.70
$527.04M0.93153,253 shs129,601 shs
DermTech, Inc. stock logo
DMTK
DermTech
$0.64
+8.4%
$0.86
$0.59
$4.36
$20.46M2.52178,527 shs677,550 shs
Personalis, Inc. stock logo
PSNL
Personalis
$1.29
+6.6%
$1.45
$0.89
$2.67
$61.11M1.95221,423 shs281,034 shs
RadNet, Inc. stock logo
RDNT
RadNet
$46.52
-2.3%
$44.81
$25.11
$49.94
$3.26B1.69506,661 shs594,495 shs
Renalytix Plc stock logo
RNLX
Renalytix
$0.80
+2.6%
$0.93
$0.24
$4.04
$39.22M3.03193,621 shs30,126 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
+0.57%-3.74%-5.11%+0.78%-18.04%
DermTech, Inc. stock logo
DMTK
DermTech
+8.97%+3.54%-6.80%-48.89%-85.43%
Personalis, Inc. stock logo
PSNL
Personalis
+6.61%+1.18%-14.57%-14.00%-51.32%
RadNet, Inc. stock logo
RDNT
RadNet
-2.29%-4.08%-1.46%+23.13%+69.23%
Renalytix Plc stock logo
RNLX
Renalytix
+1.65%-10.66%-11.87%+208.94%-67.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
1.9459 of 5 stars
3.51.00.00.02.72.50.6
DermTech, Inc. stock logo
DMTK
DermTech
0.8238 of 5 stars
3.01.00.00.01.60.01.3
Personalis, Inc. stock logo
PSNL
Personalis
3.9692 of 5 stars
3.53.00.04.20.02.51.3
RadNet, Inc. stock logo
RDNT
RadNet
3.6392 of 5 stars
2.32.00.04.62.01.71.9
Renalytix Plc stock logo
RNLX
Renalytix
2.0969 of 5 stars
3.55.00.00.02.00.80.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$31.0060.54% Upside
DermTech, Inc. stock logo
DMTK
DermTech
2.00
Hold$2.38269.05% Upside
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$5.50326.36% Upside
RadNet, Inc. stock logo
RDNT
RadNet
2.67
Moderate Buy$53.6715.36% Upside
Renalytix Plc stock logo
RNLX
Renalytix
3.00
Buy$5.00523.44% Upside

Current Analyst Ratings

Latest PSNL, RDNT, RNLX, DMTK, and CSTL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$0.63
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$1.50
4/19/2024
DermTech, Inc. stock logo
DMTK
DermTech
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
4/11/2024
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50
3/28/2024
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$51.00 ➝ $55.00
3/22/2024
RadNet, Inc. stock logo
RDNT
RadNet
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$47.00 ➝ $58.00
3/6/2024
RadNet, Inc. stock logo
RDNT
RadNet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$48.00
3/5/2024
DermTech, Inc. stock logo
DMTK
DermTech
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$2.50 ➝ $1.50
3/4/2024
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $51.00
3/1/2024
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $28.00
3/1/2024
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$33.00 ➝ $37.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$219.79M2.41N/AN/A$14.54 per share1.33
DermTech, Inc. stock logo
DMTK
DermTech
$15.30M1.46N/AN/A$1.67 per share0.39
Personalis, Inc. stock logo
PSNL
Personalis
$73.48M0.89N/AN/A$2.64 per share0.49
RadNet, Inc. stock logo
RDNT
RadNet
$1.62B1.97$3.26 per share14.29$11.79 per share3.95
Renalytix Plc stock logo
RNLX
Renalytix
$3.40M11.79N/AN/A$0.15 per share5.35

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$57.47M-$2.16N/AN/AN/A-26.15%-14.92%-13.20%5/2/2024 (Confirmed)
DermTech, Inc. stock logo
DMTK
DermTech
-$100.89M-$3.14N/AN/AN/A-659.57%-123.96%-67.94%5/2/2024 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$108.30M-$2.25N/AN/AN/A-147.38%-61.42%-41.05%5/1/2024 (Estimated)
RadNet, Inc. stock logo
RDNT
RadNet
$3.04M-$0.02N/A89.46N/A0.19%4.72%1.29%5/14/2024 (Estimated)
Renalytix Plc stock logo
RNLX
Renalytix
-$45.61M-$0.45N/AN/A-1,736.47%-1,008.88%-155.62%6/14/2024 (Estimated)

Latest PSNL, RDNT, RNLX, DMTK, and CSTL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.37N/A+$0.37N/AN/AN/A  
3/1/2024Q4 2023
RadNet, Inc. stock logo
RDNT
RadNet
$0.11$0.20+$0.09$0.43$410.11 million$420.38 million    
2/29/2024Q4 2023
DermTech, Inc. stock logo
DMTK
DermTech
-$0.54-$0.56-$0.02-$0.56$4.05 million$3.92 million
2/28/2024Q4 2023
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.84-$0.10+$0.74-$0.10$51.32 million$66.12 million
2/28/2024Q4 2023
Personalis, Inc. stock logo
PSNL
Personalis
-$0.53-$0.46+$0.07-$0.38$19.56 million$19.68 million
2/14/2024Q2 2024
Renalytix Plc stock logo
RNLX
Renalytix
-$0.09-$0.09N/A-$0.09$0.70 million$0.71 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
DermTech, Inc. stock logo
DMTK
DermTech
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/A
6.20
6.04
DermTech, Inc. stock logo
DMTK
DermTech
N/A
4.59
4.52
Personalis, Inc. stock logo
PSNL
Personalis
N/A
3.11
2.88
RadNet, Inc. stock logo
RDNT
RadNet
1.00
1.32
1.32
Renalytix Plc stock logo
RNLX
Renalytix
N/A
0.59
0.59

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
DermTech, Inc. stock logo
DMTK
DermTech
20.45%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%
Renalytix Plc stock logo
RNLX
Renalytix
9.92%

Insider Ownership

CompanyInsider Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
7.70%
DermTech, Inc. stock logo
DMTK
DermTech
5.10%
Personalis, Inc. stock logo
PSNL
Personalis
4.10%
RadNet, Inc. stock logo
RDNT
RadNet
4.43%
Renalytix Plc stock logo
RNLX
Renalytix
18.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
61027.45 million25.34 millionOptionable
DermTech, Inc. stock logo
DMTK
DermTech
20634.62 million32.86 millionOptionable
Personalis, Inc. stock logo
PSNL
Personalis
22350.50 million48.43 millionOptionable
RadNet, Inc. stock logo
RDNT
RadNet
10,28868.47 million65.44 millionOptionable
Renalytix Plc stock logo
RNLX
Renalytix
10249.97 million40.82 millionOptionable

PSNL, RDNT, RNLX, DMTK, and CSTL Headlines

SourceHeadline
Renalytix files to sell 19.99M ordinary shares for holdersRenalytix files to sell 19.99M ordinary shares for holders
msn.com - April 17 at 5:42 PM
Renalytix Sells Stock to Raise Up to $4 MlnRenalytix Sells Stock to Raise Up to $4 Mln
marketwatch.com - April 9 at 9:13 AM
Renalytix Announces Financing with Expected Size of up to $4 MillionRenalytix Announces Financing with Expected Size of up to $4 Million
globenewswire.com - April 8 at 7:00 AM
3 Ridiculously Enticing Stocks to Buy for Under a Buck3 Ridiculously Enticing Stocks to Buy for Under a Buck
investorplace.com - March 25 at 3:58 PM
KidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)KidneyIntelX(TM) included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
stockhouse.com - March 14 at 9:25 AM
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
globenewswire.com - March 14 at 7:00 AM
Google restricts election queries by AI model Gemini - reportGoogle restricts election queries by AI model Gemini - report
msn.com - March 12 at 10:33 AM
New Zealand air-safety authorities to seize flight recorders for Latam 787New Zealand air-safety authorities to seize flight recorders for Latam 787
msn.com - March 12 at 10:33 AM
Buy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market ProspectsBuy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and Strong Market Prospects
markets.businessinsider.com - March 5 at 12:59 AM
Why Is AI-Powered Diagnostic Firm Renalytix Stock Soaring On Monday?Why Is AI-Powered Diagnostic Firm Renalytix Stock Soaring On Monday?
msn.com - March 4 at 2:58 PM
Renalytix approached by potential buyer, stock rallies 28%Renalytix approached by potential buyer, stock rallies 28%
msn.com - March 4 at 2:58 PM
Why Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today?Why Is Kidney-Disease Diagnostic Focused Renalytix Stock Trading Higher Today?
msn.com - February 29 at 2:33 PM
Renalytix Plc - Depositary Receipt () (RNLX) Price Target Increased by 21.81% to 5.97Renalytix Plc - Depositary Receipt () (RNLX) Price Target Increased by 21.81% to 5.97
msn.com - February 24 at 9:53 AM
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
finance.yahoo.com - February 15 at 8:41 AM
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
globenewswire.com - February 15 at 7:00 AM
Renalytix slides by a third as funding moves front and centreRenalytix slides by a third as funding moves front and centre
proactiveinvestors.co.uk - February 15 at 6:38 AM
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.33%U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.33%
msn.com - February 13 at 10:09 AM
Renalytix surges after Medicare draft decision on lead productRenalytix surges after Medicare draft decision on lead product
msn.com - February 12 at 7:34 PM
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000
msn.com - February 11 at 9:54 AM
Renalytix AI Anticipates Medicare Coverage MilestoneRenalytix AI Anticipates Medicare Coverage Milestone
markets.businessinsider.com - February 10 at 8:18 AM
Strong Buy for Renalytix AI: Undervalued Stock with Promising Market Prospects and Strategic Growth CatalystsStrong Buy for Renalytix AI: Undervalued Stock with Promising Market Prospects and Strategic Growth Catalysts
markets.businessinsider.com - February 9 at 10:45 AM
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceRenalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
globenewswire.com - February 9 at 9:00 AM
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney diseaseNew published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
finance.yahoo.com - January 10 at 8:06 AM
BTIG Keeps Their Buy Rating on Renalytix AI (RNLX)BTIG Keeps Their Buy Rating on Renalytix AI (RNLX)
markets.businessinsider.com - December 31 at 11:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Castle Biosciences logo

Castle Biosciences

NASDAQ:CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
DermTech logo

DermTech

NASDAQ:DMTK
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.
Personalis logo

Personalis

NASDAQ:PSNL
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
RadNet logo

RadNet

NASDAQ:RDNT
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
Renalytix logo

Renalytix

NASDAQ:RNLX
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.